AU2020253621A1 - Methods of depleting disease causing agents via antibody targeted phagocytosis - Google Patents
Methods of depleting disease causing agents via antibody targeted phagocytosis Download PDFInfo
- Publication number
- AU2020253621A1 AU2020253621A1 AU2020253621A AU2020253621A AU2020253621A1 AU 2020253621 A1 AU2020253621 A1 AU 2020253621A1 AU 2020253621 A AU2020253621 A AU 2020253621A AU 2020253621 A AU2020253621 A AU 2020253621A AU 2020253621 A1 AU2020253621 A1 AU 2020253621A1
- Authority
- AU
- Australia
- Prior art keywords
- dectin
- antibody
- cells
- phagocytosis
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962830139P | 2019-04-05 | 2019-04-05 | |
| US62/830,139 | 2019-04-05 | ||
| PCT/US2020/026721 WO2020206354A1 (en) | 2019-04-05 | 2020-04-03 | Methods of depleting disease causing agents via antibody targeted phagocytosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020253621A1 true AU2020253621A1 (en) | 2021-11-11 |
Family
ID=72667025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020253621A Pending AU2020253621A1 (en) | 2019-04-05 | 2020-04-03 | Methods of depleting disease causing agents via antibody targeted phagocytosis |
Country Status (12)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019000071A2 (pt) | 2016-07-07 | 2019-07-02 | Bolt Biotherapeutics Inc | conjugados adjuvantes de anticorpo |
| EP3937984A1 (en) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| IL297782A (en) | 2020-05-01 | 2022-12-01 | Bolt Biotherapeutics Inc | Anti-dectin-2 antibodies |
| EP4225373A4 (en) | 2020-10-07 | 2025-01-08 | Dren Bio, Inc. | ANTI-DECTIN-1 ANTIBODIES AND METHODS OF USE THEREOF |
| KR20240170833A (ko) * | 2022-04-04 | 2024-12-04 | 드렌 바이오, 인크. | 덱틴-1 및 cd20에 결합하는 다중특이성 결합 단백질 및 이의 사용 방법 |
| KR20250006353A (ko) * | 2022-04-04 | 2025-01-10 | 드렌 바이오, 인크. | 항-덱틴-1 항체 및 이의 사용 방법 |
| AU2024316588A1 (en) * | 2023-07-31 | 2026-01-29 | Dren Bio Management, Inc. | Multispecific binding proteins that bind dectin-1 and trop-2 and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI423985B (zh) * | 2007-02-23 | 2014-01-21 | 貝勒研究協會 | 利用dectin-1活化人類抗原呈現細胞之醫療應用 |
| US20120244155A1 (en) * | 2011-03-22 | 2012-09-27 | Baylor Research Institute | Dendritic Cells (DCs) Targeting for Tuberculosis (TB) Vaccine |
| WO2018176159A1 (en) * | 2017-03-31 | 2018-10-04 | Zymeworks Inc. | Tumor antigen presentation inducer constructs and uses thereof |
| TW201904588A (zh) * | 2017-06-25 | 2019-02-01 | 美商西雅圖免疫公司 | 引導及導航控制蛋白質之製造及使用方法 |
| CN112567026B (zh) * | 2018-07-19 | 2024-08-23 | 昂科霍斯特公司 | Il-31改善用于癌症的基于巨噬细胞的过继性细胞疗法的功效 |
| SG11202100555PA (en) * | 2018-07-27 | 2021-02-25 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
-
2020
- 2020-04-03 SG SG11202110663UA patent/SG11202110663UA/en unknown
- 2020-04-03 CA CA3136272A patent/CA3136272A1/en active Pending
- 2020-04-03 CN CN202080038435.9A patent/CN114502585A/zh active Pending
- 2020-04-03 JP JP2021560416A patent/JP2022527646A/ja not_active Withdrawn
- 2020-04-03 BR BR112021019950A patent/BR112021019950A2/pt unknown
- 2020-04-03 KR KR1020217036237A patent/KR20220031995A/ko not_active Ceased
- 2020-04-03 US US17/601,359 patent/US20220169737A1/en not_active Abandoned
- 2020-04-03 EP EP20784394.7A patent/EP3947467A4/en active Pending
- 2020-04-03 MX MX2021012035A patent/MX2021012035A/es unknown
- 2020-04-03 WO PCT/US2020/026721 patent/WO2020206354A1/en not_active Ceased
- 2020-04-03 AU AU2020253621A patent/AU2020253621A1/en active Pending
-
2021
- 2021-10-04 IL IL286967A patent/IL286967A/en unknown
-
2024
- 2024-12-10 US US18/975,761 patent/US20250206826A1/en active Pending
-
2025
- 2025-04-01 JP JP2025060435A patent/JP2025096316A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250206826A1 (en) | 2025-06-26 |
| US20220169737A1 (en) | 2022-06-02 |
| CA3136272A1 (en) | 2020-10-08 |
| KR20220031995A (ko) | 2022-03-15 |
| EP3947467A1 (en) | 2022-02-09 |
| IL286967A (en) | 2021-12-01 |
| BR112021019950A2 (pt) | 2021-12-07 |
| JP2022527646A (ja) | 2022-06-02 |
| SG11202110663UA (en) | 2021-10-28 |
| EP3947467A4 (en) | 2023-01-04 |
| CN114502585A (zh) | 2022-05-13 |
| MX2021012035A (es) | 2022-03-11 |
| WO2020206354A1 (en) | 2020-10-08 |
| JP2025096316A (ja) | 2025-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250206826A1 (en) | Methods of depleting disease causing agents via antibody targeted phagocytosis | |
| AU2015357122B2 (en) | Bispecific antibodies against CD3epsilon and BCMA for use in treatment of diseases | |
| US20260035469A1 (en) | Anti-dectin-1 antibodies and methods of use thereof | |
| JP2021515568A (ja) | 腫瘍特異的細胞枯渇のための抗cd25 | |
| KR20200104299A (ko) | 항 lag-3 항체 및 이의 용도 | |
| JP7299873B2 (ja) | Cd38抗体 | |
| EP4493592A1 (en) | Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells | |
| JP2022525937A (ja) | Btn2に対する特異性を有する抗体及びその使用 | |
| US20230192900A1 (en) | Bispecific antibodies binding hvem and cd9 | |
| HK40102072A (en) | Bispecific antibodies against cd3epsilon and bcma for use in treatment of diseases | |
| WO2023081915A1 (en) | Il-8 as a predictive biomarker and methods of use thereof for the treatment of cancer | |
| HK1244491B (en) | Bispecific antibodies against cd3epsilon and bcma for use in treatment of diseases | |
| HK1244491A1 (en) | Bispecific antibodies against cd3epsilon and bcma for use in treatment of diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: TO AMEND THE APPLICANT NAME TO DREN BIO MANAGEMENT, INC. |